IBCSG 45-13 PANACEA

  • A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers.

  • Chairs
    Dr. Sherene Loi, Peter MacCallum Cancer Center
    Prof. Fabrice Andre, Institut Gustave Roussy

    Statistician
    Anita Giobbie-Hurder

    Director of the Data Management Center
    Holly Shaw


    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    May 9, 2014

    Targeted Accrual
    between 6 and 61 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login